IRAK1 and endometrial cancer: In a similar way, the inhibition of the epithelial-mesenchymal transition in endometrial cancer cells has been achieved via treatment with miR-192-5p expressed in TAM-derived EVs, via the inhibition of the Interleukin 1 Receptor Associated Kinase 1 (IRAK1)/NFκB signaling pathway [125].